(Senaparib + temozolomide) is under clinical development by IMPACT Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Senaparib + temozolomide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Senaparib + temozolomide) overview
Senaparib (IMP-4297) in combination with temozolomide (TMZ) is under development for the treatment of solid tumor including triple-negative breast cancer (TNBC), SCLC, ovarian cancer (OC) and metastatic castration-resistant prostate cancer (mCRPC). It is a fixed dose combination. Senaparib acts by targeting PARP (Poly(ADP-ribose) polymerase) and temozolomide act by targeting DNA synthesis and is administered in the form of capsule.
IMPACT Therapeutics overview
IMPACT Therapeutics (IMPACT) is a developer of therapeutics to treat cancer and other life-threatening diseases. The company provides products such as microtubule inhibitors, PARP-1 inhibitors, and Hedgehog pathway inhibitors for oncology. Its PARP-1 inhibitor is an oral bioavailability; and IMP04297 is an efficacious in several animal cancer models. The company also develops IMP3138, a small molecular microtubule inhibitor clinical candidate with advantages in vitro and in vivo over paclitaxel. It also operates oncology drug discovery and several anticancer drug development projects. IMPACT is headquartered in Nanjing, China.
For a complete picture of (Senaparib + temozolomide)’s drug-specific PTSR and LoA scores, buy the report here.